Skip to content

A study of the chamomile on sleep quality.

An exploratory study of the effect of the chamomile essential oil on sleep quality

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs051210031
Enrollment
19
Registered
2021-06-02
Start date
2021-07-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Person with any condition that causes a need for care in welfare facilities for older people, etc.

Interventions

Chamomile essential oil 1.2g / day or air is released intermittently once a day from bedtime to waking up for 7 consecutive days.

Sponsors

Okayama Masanobu
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Resident of welfare facilities for older people, etc. 2. Person aged 20 years old or older. 3. Person with Pittsburgh Sleep Questionnaire Quality Index of 2 or higher 4. Person with no willingness to change the drug being taken during the study period. 5. Person who voluntarily consented to the document regarding participation in this study.

Exclusion criteria

Exclusion criteria: 1. Person with drug hypersensitivities such as aromas of essential oils. 2. Pregnant and lactating woman, or woman of childbearing potential. 3. Person inappropriately participating in this study at the discretion of the person in charge of this study.

Design outcomes

Primary

MeasureTime frame
Sleep quality: Changes in the score of the Pittsburgh Sleep Questionnaire revised from the original to the one-week version (change from the score on the first day of the release observation period as the baseline to the score on the first day of the post-release observation period ).

Secondary

MeasureTime frame
Effectiveness evaluation outcomes: Changes in the time of wake-up in the sleep period that is counted by the heart rate and respiratory rate measured by the under-bed sensor. (change from the total time during the pre-release period as the baseline to the total time during the release period) Safety evaluation outcomes: Incidence of diseases during the observation period.

Contacts

Public ContactMasanobu Okayama

Kobe University Graduate School of Medicine

okayamam@med.kobe-u.ac.jp+81-78-382-6732

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026